Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis

Antimicrob Agents Chemother. 1996 Feb;40(2):503-5. doi: 10.1128/AAC.40.2.503.

Abstract

We studied 122 stool samples collected from 25 patients with hematologic malignancies who received prophylactic norfloxacin. Fecal samples were obtained at admission and twice weekly thereafter during prophylaxis. Fluoroquinolone-resistant Escherichia coli strains were isolated from the feces of 10 (40%) of the patients; two patients had fluoroquinolone-resistant E. coli strains prior to beginning norfloxacin treatment, and in the other eight patients, the strains appeared subsequently. One patient developed fluoroquinolone-resistant E. coli bacteremia after 10 days of norfloxacin administration.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • DNA, Bacterial / analysis
  • Drug Resistance, Microbial / genetics
  • Electrophoresis, Gel, Pulsed-Field
  • Escherichia coli / drug effects*
  • Escherichia coli / genetics
  • Feces / microbiology*
  • Female
  • Humans
  • Leukemia / drug therapy
  • Lymphoma / drug therapy
  • Male
  • Middle Aged
  • Multiple Myeloma / drug therapy
  • Neoplasms / drug therapy*
  • Neoplasms / microbiology
  • Norfloxacin / therapeutic use*
  • Opportunistic Infections / prevention & control*

Substances

  • Anti-Infective Agents
  • DNA, Bacterial
  • Norfloxacin